Stent graft system for early clinical evaluation

Medtronic, Inc. is developing a new stent graft system designed to repair thoracic aortic aneurysm. It has been selected by the FDA for an early feasibility pilot program, allowing it to be evaluated at an early stage for proof of principle and safety data. The Valiant Mona LSA system is a stent graft designed to repair a descending thoracic aortic aneurysm encroaching on the left subclavian artery (LSA). It is based of the current market-leading Valiant Captivia Thoracic Stent Graft, which is approved by the FDA for treating aneurysms, penetrating ulcers and other conditions related to the descending thoracic aorta. “Our Valiant Mona LSA system could potentially obviate the need for LSA bypass procedures, extending the benefits of endovascular repair without surgery to more patients with thoracic aortic aneurysms,” Tony Semedo, vice president and general manager of the company’s Endovascular Therapies business, said.